Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review

Area of Science:

• Molecular Biology
• Oncology
• Dermatology

Background:

• The mitogen-activated protein kinase (MAPK) signaling pathway is crucial in cellular signaling and is frequently dysregulated in cancer.
• Over 50% of cutaneous melanomas harbor mutations in MAPK pathway components, with BRAF and NRAS being the most common.
• BRAF mutations are particularly significant drivers in melanoma pathogenesis.

Purpose of the Study:

• To provide an updated review on the role of the MAPK signaling pathway in cutaneous melanoma.
• To focus on various BRAF mutations and their diagnostic and therapeutic implications.
• To highlight the challenges in standardizing BRAF mutation testing.

Main Methods:

• Literature review of scientific publications on MAPK signaling, melanoma pathogenesis, BRAF mutations, and targeted therapies.
• Analysis of diagnostic and therapeutic strategies related to specific BRAF mutations.
• Discussion of current challenges in molecular assay standardization for BRAF testing.

Main Results:

• The MAPK pathway, especially BRAF mutations, plays a central role in the development of cutaneous melanoma.
• Targeted therapies for BRAF-mutant melanoma have been developed, necessitating accurate molecular diagnostics.
• Standardization of BRAF mutation detection assays remains an ongoing challenge.

Conclusions:

• The MAPK pathway is a key target in melanoma research and treatment.
• Understanding specific BRAF mutations is critical for guiding personalized therapeutic decisions in melanoma patients.
• Further efforts are needed to standardize molecular diagnostic testing for BRAF mutations in melanoma.